Anti-D monoclonal antibodies
The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
1. A method of treating cancer comprising administering to a patient in need thereof a monoclonal antibody composition specific to said cancer, wherein said composition comprises purified monoclonal antibodies having on the Fcγ glycosylation site (Asn 297, EU numbering) bi-antennary glycan structures, wherein said glycan structures of the purified monoclonal antibodies have a fucose content less than 30%.
2. The method of claim 1 , wherein the fucose content is between 20% and 30%.
3. The method of claim 2 , wherein the fucose content is between 25% and 30%.
4. The method of claim 1 , wherein said glycan structures of the purified monoclonal antibodies have a sialic acid content of less than 25%.
5. The method of claim 1 , wherein the purified monoclonal antibodies are directed against an antigen, and activate effector cells expressing Fcγ type III receptors, causing a lysis of target cells presenting the antigen greater than 60% of a lysis caused by polyclonal antibodies directed against the antigen.
6. The method of claim 1 , wherein the purified monoclonal antibodies are directed against an antigen, and activate effector cells expressing Fcγ type III receptors, causing a lysis of target cells presenting the antigen greater than 90% of a lysis caused by polyclonal antibodies directed against the antigen.
7. The method of claim 1 , wherein the purified monoclonal antibodies are IgG1 antibodies.
8. The method of claim 1 , wherein the purified monoclonal antibodies are IgG3 antibodies.
9. A method of treating cancer comprising administering to a patient in need thereof a monoclonal antibody composition specific to said cancer, wherein said composition comprises purified monoclonal antibodies having on the Fcγ glycosylation site (Asn 297, EU numbering) bi-antennary glycan structures, wherein said glycan structures of the purified monoclonal antibodies have a content less than 30% for the G0F+G1F forms.
10. The method of claim 9 , wherein said glycan structures of the purified monoclonal antibodies have a sialic acid content of less than 25%.
11. The method of claim 9 , wherein the monoclonal antibodies are directed against an antigen, and activate effector cells expressing Fcγ type III receptors, causing a lysis of target cells presenting the antigen greater than 60% of a lysis caused by polyclonal antibodies directed against the antigen.
12. The method of claim 11 , wherein the monoclonal antibodies cause a lysis of target cells presenting the antigen greater than 70% of a lysis caused by polyclonal antibodies directed against the antigen.
13. The method of claim 12 , wherein the monoclonal antibodies cause a lysis of target cells presenting the antigen greater than 80% of a lysis caused by polyclonal antibodies directed against the antigen.
14. The method of claim 13 , wherein the monoclonal antibodies cause a lysis of target cells presenting the antigen greater than 90% of a lysis caused by polyclonal antibodies directed against the antigen.
15. The method of claim 9 , wherein said monoclonal antibodies are IgG1 antibodies.
16. The method of claim 9 , wherein said monoclonal antibodies are IgG3 antibodies.